Insider Selling: Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells $25,470.00 in Stock

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 1,800 shares of the stock in a transaction dated Monday, October 13th. The stock was sold at an average price of $14.15, for a total transaction of $25,470.00. Following the transaction, the chief executive officer owned 198,533 shares in the company, valued at approximately $2,809,241.95. The trade was a 0.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cadrenal Therapeutics Stock Performance

CVKD stock opened at $13.82 on Friday. The firm has a market cap of $28.33 million, a price-to-earnings ratio of -1.56 and a beta of 0.96. The firm has a 50-day simple moving average of $13.21 and a two-hundred day simple moving average of $13.65. Cadrenal Therapeutics, Inc. has a one year low of $8.74 and a one year high of $22.90.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its quarterly earnings results on Monday, August 11th. The company reported ($1.87) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.27). As a group, equities analysts predict that Cadrenal Therapeutics, Inc. will post -7.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $32.00.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.